INFLUENCE OF CHRONIC NEUROGENIC PAIN ON DYNAMICS OF ENDOTHELIN-1 LEVEL AND COMPONENTS OF NO-SYSTEM DURING MELANOMA B16/F10 GROWTH
- Authors: Kit O.I1, Kotieva I.M1, Frantsiyants E.M1, Surikova E.I.1, Kaplieva I.V1, Bandovkina V.A1, Trepitaki L.K1, Pogorelova J.A1
-
Affiliations:
- Rostov Research Institute of Oncology
- Issue: Vol 23, No 3-6 (2018)
- Pages: 180-188
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/42991
- DOI: https://doi.org/10.18821/1028-9984-2018-23-3-6-180-188
- ID: 42991
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
O. I Kit
Rostov Research Institute of Oncology344037, Rostov-on-Don, Russia
I. M Kotieva
Rostov Research Institute of Oncology344037, Rostov-on-Don, Russia
E. M Frantsiyants
Rostov Research Institute of Oncology344037, Rostov-on-Don, Russia
Ekaterina I. Surikova
Rostov Research Institute of Oncology
Email: super.gormon@ya.ru
MD, PhD, Senior Researcher at Laboratory of Malignant tumor pathogenesis study, Rostov Research Institute of Oncology, 344037, Rostov-on-Don, Russian Federation 344037, Rostov-on-Don, Russia
I. V Kaplieva
Rostov Research Institute of Oncology344037, Rostov-on-Don, Russia
V. A Bandovkina
Rostov Research Institute of Oncology344037, Rostov-on-Don, Russia
L. K Trepitaki
Rostov Research Institute of Oncology344037, Rostov-on-Don, Russia
Ju. A Pogorelova
Rostov Research Institute of Oncology344037, Rostov-on-Don, Russia
References
- Данилов А.Б., Давыдов О.С. Эпидемиология нейропатической боли. Ж. Боль. 2007; 17 (4): 12-16.
- Яхно Н.Н., Кукушкин М.Л., Давыдов О.С., Данилов А.Б., Амелин А.В., Куликов С.М. Результаты Российского эпидемиологического исследования распространенности нейропатической боли, ее причин и характеристик в популяции амбулаторных больных, обратившихся к врачу-неврологу. Ж. Боль. 2008; 18 (3): 24-32.
- Worldwide palliative care alliance (WPCA); World Health Organization. 2015. www.who.int/nmh/Global_Atlas_of_Palliative_ Care.pdf
- Paice J.A., Bell R.F., Kalso E.A., Soyannwo O.A. Cancer Pain. From Molecules to Saffering. IASP Press. Seattle; 2010.
- Кукушкин М.Л. Этиопатегенетические принципы лечения хронической боли. Русский мед. журнал. 2007; 15 (10): 827-32.
- Кит О.И., Франциянц Е.М., Котиева И.М., Каплиева И.В., Трепитаки Л.К., Бандовкина В.А. и др. Некоторые механизмы повышения злокачественности меланомы на фоне хронической боли у самок мышей. Российский журнал боли. 2017; 53 (2): 14-20.
- Saleh A., Stathopoulou M.G., Dadé S., Ndiaye N.C., Azimi-Nezhad M., Murray H. et al. Angiogenesis related genes NOS3, CD14, MMP3 and IL4R are associated to VEGF gene expression and circulating levels in healthy adults. BMC Med Genet. 2015. doi: 10.1186/s12881-015-0234-6.
- Lankhorst S., Danser A.H., van den Meiracker A.H. Endothelin-1 and antiangiogenesis. Am. J. Physiol Regul. Integr. Comp. Physiol. 2016, 310 (3):230-4. doi: 10.1152/ajpregu.00373.2015.
- Smith T.P., Haymond T., Smith S.N., Sweitzer S.M. Evidence for the endothelin system as an emerging therapeutic target for the treatment of chronic pain. Journal of pain research. 2014; (7): 531-4.
- Yang Y., Zhang J., Liu Y., Zheng Y., Bo J., Zhou X. et al. Role of nitric oxide synthase in the development of bone cancer pain and effect of L-NMMA. Mol. Med. Rep. 2016, 13(2):1220-1226. doi: 10.3892/mmr. 2015.4647.
- Koschembahr A.M. von, Swope V.B., Starner R.J., Abdel-Malek Z.A. Endothelin-1 protects human melanocytes from UV-induced DNA damage by activating JNK and p38 signaling pathways. Exp. Dermatol. 2015. doi: 10.1111/exd.12638.
- Willey K.E. Davenport A.P. Nitric oxide-medulation of the endothelin-1 signaling pathway in the human cardiovascular system. Brit. J. Pharmacology. 2001; 132: 213-20.
- Pirtskhalaishvili G., Nelson J.B. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate. 2000; 44 (1): 77-87.
- Lalich M., McNeel D.G., Wilding G., Liu G. Endothelin receptor antagonists in cancer therapy. Cancer Invest. 2007; 25 (8): 785-94.
- Rosanò L., Spinella F., Bagnato A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat.Rev. Cancer. 2013а; 13: 637-51.
- Davenport A.P. Hyndman K.A., Dhaun N., Southan C. et al. Endothelin. Pharmacological reviews. 2016; 68 (2): 357-418.
- Bagnato A., Rosan Õ.L, Spinella F., Di Castro V., Tecce R., Natali P.G. Endothelin B receptor blockade inhibits dynamic of cell interactions and communications in melanoma cell progression. Cancer Research. 2004; 64: 1436-43.
- Murase D. Cooperation of endothelin-1 signaling with melanosomes plays a role in developing and/or maintaining human skin hyperpigmentation Biol. Open. 2015; 4 (10): 1213-21.
- Irani S., Salajegheh A., Smith R.A., Lam A.K. A review of the profile of endothelin axis in cancer and its management. Crit. Rev. Oncol. Hematol. 2014; 89: 314-21.
- Papanikolaou S., Bravou V., Papadaki H., Gyftopoulos K. The role of the endothelin axis in promoting epithelial to mesenchymal transition and lymph node metastasis in prostate adenocarcinoma. Urol. Ann. 2017, 9(4):372-379. doi: 10.4103/UA.UA_43_17.
- Wu M.H., Huang C.Y., Lin J.A., Wang S.W., Peng C.Y., Cheng H.C., Tang CH. Endothelin-1 promotes vascular endothelial growth factor-dependent angiogenesis in human chondrosarcoma cells. Oncogene. 2014; 33 (13): 1725-35. doi: 10.1038/onc.2013.109.
- Shi L., Zhou S.S., Chen W.B., Xu L. Functions of endothelin-1 in apoptosis and migration in hepatocellular carcinoma. Exp. Ther. Med. 2017, 13(6):3116-3122. doi: 10.3892/etm.2017.4314.
- Nelson J.B., Udan M.S., Guruli G., Pflug B.R. Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia. 2005; 7 (7): 631-7.
- Lankhorst S., Kappers M.H., van Esch J.H., Danser A.H., van den Meiracker A.H. Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress. Antioxid. Redox Signal. 2014; 20 (1): 135-45. doi: 10.1089/ars.2013.5244.
- Vahora H., Khan M.A., Alalami U., Hussain A. The Potential Role of Nitric Oxide in Halting Cancer Progression Through Chemoprevention. J. Cancer Prev. 2016; 21 (1): 1-12. doi: 10.15430/JCP.2016.21.1.1. Epub 2016 Mar 30.
- Lahdenranta J., Hagendoorn J., Padera T.P., Hoshida T., Nelson G., Kashiwagi, S. Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis. Cancer Res. 2009; 69: 2801-8.
- Ridnour L.A., Windhausen A.N., Isenberg J.S., Yeung N., Thomas D.D., Vitek M.P. Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways. Proc. Natl. Acad. Sci. U S A. 2007; 104: 16898-903.
- Mazzoni A., Bronte V., Visintin A., Spitzer J.H., Apolloni E., Serafini P. et al. Myeloid suppressor lines inhibit T-cell responses by an NO-dependent mechanism. J. Immunol. 2002; 168: 689-95.
- Nagaraj S., Gupta K., Pisarev V., Kinarsky L., Sherman S., Kang L. et al. Altered recognition of antigen is a mechanism of CD8+ T-cell tolerance in cancer. Nat. Med. 2007; (13): 828-35.
- Rodriguez P.C., Quiceno D.G., Ochoa A.C. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood. 2007; 109: 1568-73.
- Viola A., Bronte V. Metabolic mechanisms of cancer-induced inhibition of immune responses. Semin. Cancer Biol. 2007; 17(4): 309-16.